More Weakness Ahead For Biotechnology Stocks

Biotechnology stocks had a great run over the past few years but likely got ahead of themselves early this year. The current mean-reversion move to the downside in biotechnology stocks looks feels heavier and looks to have more to go. Here is how I am measuring the downside targets.

Serge Berger

Submit a Comment

Your email address will not be published. Required fields are marked *

Get Our Free Daily Trading Videos

Delivered To your Inbox

By submitting your information you agree to our Terms of Service and our Privacy Policy